XP0.F Xenon Pharmaceuticals Inc

Healthcare Biotechnology Frankfurt Exchange
36.60 EUR
Close of Nov 13, 2026
29.40 62.00
Market cap
EUR 3.60B
P/E
-
P/B
3.52x
ROE
-37.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is XP0.F undervalued?

Graham number

The Graham number of Xenon Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Xenon Pharmaceuticals Inc fundamental analysis

No fundamental analysis for Xenon Pharmaceuticals Inc yet.

Xenon Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric di…

Full company profile